For most people who respond to TMS, the benefit lasts a year or longer. Follow-up studies show about 60 to 70 percent of responders remain well at twelve months, usually while continuing medication or therapy. Those who relapse typically do so within six months, and a re-treatment course works for the large majority of them.
TMS is not a daily pill, and it is not a permanent cure. It is a course of treatment that, for most responders, produces a remission lasting a year or more, and often considerably longer. Understanding what the data actually shows about durability helps you plan for the months after treatment ends, rather than hoping and waiting.
What the follow-up studies show
The best durability data comes from studies that tracked patients for a year after an acute TMS course.
A multi-site study published in 2014 followed patients who had responded to an acute course of NeuroStar TMS for twelve months, with patients continuing their usual medication and allowed to receive re-treatment if symptoms returned. At one year, about 62 percent of initial responders were still in response and nearly half were still in remission. About a third needed at least one re-treatment series during the year, and most of those regained their response.
BrainsWay's pivotal Deep TMS trial included a maintenance phase in which responders received twice-weekly sessions for 12 weeks after the acute course. Response was largely maintained through that period. Subsequent naturalistic follow-up data from Deep TMS clinics report one-year sustained response in a similar range to figure-8 systems, roughly 60 to 70 percent.
Longer-term registry data, out to two and three years, is thinner but consistent: a majority of responders remain well, a minority relapse and are re-treated, and a smaller minority do not regain their response.
Why TMS effects persist
TMS does not leave anything in the body. The persistence comes from what it does to brain circuits. Repeated stimulation over six weeks appears to strengthen connectivity in the prefrontal network that regulates mood and weakens the overactivity in deeper regions associated with rumination and threat. Imaging studies show these connectivity changes outlast the treatment by months, which lines up with the clinical durability.
Continuing an antidepressant or psychotherapy after the course appears to help lock in those changes. Most patients in the follow-up studies did so. Stopping all treatment the day TMS ends is possible but is associated with higher relapse rates.
Who stays well and who relapses
Several factors predict a durable response.
- Depth of initial response. Patients who reach full remission during the course hold their gains better than those who improve partially. This is one reason we encourage completing all 36 sessions rather than stopping once you feel somewhat better.
- Fewer prior episodes. Depression that has recurred many times tends to recur again, regardless of treatment.
- Continuing treatment. Medication, therapy or both after the course.
- Addressing contributors. Sleep apnea, alcohol use, thyroid problems and chronic stress that are left unaddressed shorten remissions.
- Early intervention when symptoms return. A few sessions at the first sign of relapse often prevent a full episode.
Relapse, when it happens, tends to occur in the first six months after the course. Patients who are still well at one year have a good chance of staying well for considerably longer.
Maintenance TMS
Maintenance means scheduled sessions after the acute course, intended to prevent relapse rather than treat one. Protocols vary: some clinics taper from five sessions a week to one a week over a month, then to one every two to four weeks; others schedule a short cluster of sessions monthly. The evidence that maintenance reduces relapse is reasonable but not as strong as the evidence for the acute course, and insurers have been slow to cover it.
In practice, we recommend maintenance for patients with a history of frequent relapse, those who cannot tolerate medication, and those who have relapsed after a prior TMS course. Coverage is reviewed case by case and some maintenance sessions are self-pay.
Re-treatment
Re-treatment means a new course, or a shortened course, after relapse. This is well supported by data. In the one-year follow-up study mentioned above, patients who relapsed and were re-treated regained response in about 80 percent of cases, typically within two to three weeks rather than the four to six weeks of an initial course. Response to a prior course is the strongest predictor of response to the next one.
Insurance, including Medicare, generally covers a re-treatment course if the record shows you responded to the first course and have since relapsed, with the same documentation as the original authorization.
| Strategy | What it is | When we use it | Insurance |
|---|---|---|---|
| Continuation medication or therapy | Keep existing treatment after the course | Most patients | Covered as usual |
| Taper | The final 6 sessions spread over 3 weeks | Standard end of every course | Covered as part of the course |
| Maintenance sessions | Scheduled sessions every 1 to 4 weeks | High relapse risk, medication intolerance | Inconsistent; often self-pay |
| Re-treatment course | Full or shortened course after relapse | Symptoms have returned | Usually covered with prior response documented |
How TMS durability compares with other treatments
Against medication, the comparison is in TMS's favor: a medication that works keeps working only while you take it, and tolerance or loss of effect over time is common. Against ECT, TMS responses tend to last longer without maintenance; relapse within six months after ECT exceeds 50 percent unless continuation treatment is used. Against Spravato, the picture is different because Spravato is designed as ongoing treatment with weekly or biweekly maintenance doses rather than a discrete course, so durability is built into the schedule rather than measured after it ends.
What to watch for after TMS
We ask patients to keep tracking their mood for the year after a course, ideally with the same PHQ-9 scale used during treatment, and to call at the first sign of a slide rather than waiting for a full relapse. Early warning signs are usually the ones that improved first during the course, in reverse: sleep worsens, energy drops, interest fades. A few sessions at that point is far easier than a full course later.
Follow-up visits with your psychiatrist continue after the course, typically monthly at first and then every two to three months, so medication can be adjusted and any early relapse caught.
A realistic timeline
Here is what the first year after a successful course usually looks like at Stedfast Psychiatry.
- Weeks 7 to 9: Taper sessions. Mood is typically at its best. Medication reviewed.
- Months 3 to 6: Monthly psychiatrist visits. This is the highest-risk window for relapse; most patients sail through it.
- Months 6 to 12: Visits every two to three months. Patients who are well at this point usually stay well.
- Beyond one year: Routine care. Re-treatment if and when needed.
Bottom line
TMS results last about a year for most responders and longer for many, especially when medication or therapy continues afterward. Relapse is possible, usually within six months, and re-treatment works well when it happens. The right way to think about TMS is as a treatment that produces a long remission and can be repeated, not as a one-time fix or a lifetime commitment.
Frequently asked questions
Is TMS permanent?
No treatment for depression is permanent, and TMS is no exception. For most responders the benefit lasts a year or longer, and re-treatment works well if symptoms return. Continuing medication or therapy after the course helps maintain the result.
How soon after TMS can symptoms come back?
Relapse, when it occurs, is most common in the first six months after the course. Patients who remain well at twelve months have a good chance of staying well for considerably longer. Early signs are usually worsening sleep and energy before mood drops.
Can I repeat TMS if it wears off?
Yes. Re-treatment after relapse regains response in roughly 80 percent of patients who responded the first time, often within two to three weeks. Insurance and Medicare typically cover a repeat course when the record documents the prior response and relapse.
Do I need to stay on medication after TMS?
Not necessarily, but most patients in the durability studies did, and continuing medication is associated with lower relapse rates. Your psychiatrist will decide with you whether to continue, reduce or eventually stop medication based on your history and how you respond.
Related reading
- Does TMS Work? What the Evidence Shows
- What Is TMS Therapy? A Plain-English Guide
- What to Do When Your Antidepressant Stops Working
- How Much Does TMS Cost With and Without Insurance?
This article is educational and does not replace evaluation by a licensed clinician. If you are in crisis, call or text 988.